24619-05-4

Basic information

• Product Name: 5,5'-dithiodisalicylic acid
• Synonyms: 5,5'-dithiodisalicylic acid;3,3'-Dithiobis(6-hydroxybenzoic acid);Einecs 246-360-4
• CAS NO: 24619-05-4
• Molecular Formula: C₁₄H₁₀O₆S₂
• Molecular Weight: 338.3556
• EINECS: 246-360-4
• Mol File: 24619-05-4.mol

Chemical Properties

• Boiling Point: 603.6 °C at 760 mmHg
• Flash Point: 318.9 °C
• Appearance: /
• Density: 1.75 g/cm³
• CAS DataBase Reference: 5,5'-dithiodisalicylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5,5'-dithiodisalicylic acid(24619-05-4)
• EPA Substance Registry System: 5,5'-dithiodisalicylic acid(24619-05-4)

Safety Data

• Hazardous Substances Data: 24619-05-4(Hazardous Substances Data)

Usage

Uses

Used in Analytical Chemistry:
5,5'-Dithiodisalicylic acid is used as a chelating agent for binding to metal ions, primarily in analytical chemistry applications. It is utilized to measure the concentration of metal ions in solution, providing a means to quantify and analyze these ions accurately.
Used in Research:
5,5'-Dithiodisalicylic acid is used as a subject of study for its potential antioxidant properties. Research into its ability to combat oxidative stress could lead to new insights into its use in health and medicine.
Used in Pharmaceutical Development:
5,5'-Dithiodisalicylic acid is used as a compound of interest in the development of drug delivery systems. Its metal-binding capabilities and potential biological activities suggest that it could be a useful component in the creation of targeted drug delivery mechanisms.
Used in Anticancer Research:
5,5'-Dithiodisalicylic acid is used as a candidate in anticancer research. Its potential to exhibit anticancer properties is being investigated, which could lead to the development of new therapeutic agents for the treatment of cancer.
Used in Industrial Applications:
5,5'-Dithiodisalicylic acid is used in various industrial settings due to its ability to bind to metal ions. This property can be harnessed in processes that require the removal or detection of metal ions, such as in water treatment or metal finishing industries.

Upstream product

• 21222-64-0 2-hydroxy-5-thiocyanato-benzoic acid 
• 58765-12-1 2-hydroxy-5-mercaptobenzoic acid 
• 17243-13-9 5-chlorosulfonyl-2-hydroxybenzoic acid 
• 97-05-2 5-sulfosalicylic Acid 
• 69-72-7 salicylic acid 
• 89-57-6 5-Aminosalicylic Acid 

Downstream Products

• 58765-12-1 2-hydroxy-5-mercaptobenzoic acid 

Relevant articles and documents

Ethanol catalyzed synthesis of titanocene aryl carboxylate complexes and crystal structure of (η5-C5H5) 2Ti(2-OH-5-S-O2CC6H3)2

A method for the synthesis of titanocene (IV) aryl carboxylate complexes is presented in this paper. It is based on the fact that alcohol can catalyze the reaction between Cp2TiCl2 and aryl carboxylate ligands in the presence of sodium hydroxide (NaOH). The effects of the catalyst on the reaction system were studied and the possible reaction mechanism was proposed. This method was used to prepare a series of titanocene (IV) aryl carboxylate complexes and a macrocyclic titanocene (5,5′-dithiodisalicylato titanocene), whose structure was determined by X-ray diffraction analysis.

Fe3O4@mSiO2 core-shell nanocomposite capped with disulfide gatekeepers for enzyme-sensitive controlled release of anti-cancer drugs

Multifunctional nanocarriers based on the magnetic Fe3O4 nanoparticle core and bis-(3-carboxy-4-hydroxy phenyl) disulfide (R-S-S-R1) modified mesoporous silica shell (Fe3O4@mSiO2@R-S-S-R1) were synthesized for cancer treatment through passive targeting and enzyme-sensitive drug release. Anti-cancer drug doxorubicin (DOX) was used as the model cargo to reveal the release behavior of the system. The drug loading system (DOX-Fe3O4@mSiO2@R-S-S-R1) retains the drug until it reaches the tumor tissue where glutathione reductase (GSH) can degrade the disulfide bonds and release the drug. Furthermore, the grafting amount of R-S-S-R1 can be used to adjust the release performance. All the release behaviors fit the Higuchi model very well and the release kinetics are predominated by disulfide bond degradation and mesoporous structure. With good bioactivity and targeted release performance, the system could play an important role in the development of intracellular delivery nanodevices for cancer therapy.

Bacterial reduction as means for colonic drug delivery: Can other chemical groups provide an alternative to the azo bond?

We compared the rate of colonic bacterial reduction of disulfide and nitro bonds to that of an azo counterpart. The disulfide and nitro reduction rates are comparable to that of azo having a similar molecular structure. We further explored QSAR of bacterial reduction of different nitro compounds giving a Hammett correlation with ρ = 0.553, R2 = 0.97. We conclude that disulfide and nitro compounds have an unexploited potential for use in prodrugs and drug delivery systems targeted to the colon.